BeyondSpring's Plinabulin Shows Consistent Survival Benefit in EGFR Wild-Type NSCLC After Anti-PD-(L)1 Failure
核心洞察
BeyondSpring's plinabulin plus docetaxel demonstrated clinically meaningful survival improvements in EGFR (搜索) wild-type non-squamous NSCLC patients who progressed after anti-PD-(L)1 (搜索) therapy, with median overall survival reaching 15.8 months versus 11.7 months for docetaxel alone.
The combination significantly reduced docetaxel-induced grade 4 neutropenia from 33.58% to 5.13% and decreased new brain metastasis incidence from 7.83% to 4.32%, supporting improved tolerability and clinical outcomes.
Asian subset analysis from the Phase 3 DUBLIN-3 trial showed statistically significant overall survival benefit with hazard ratio of 0.81, particularly strong in non-squamous patients with HR of 0.69.
BeyondSpring Inc. announced new analyses from its Phase 3 DUBLIN-3 study demonstrating that plinabulin plus docetaxel provides clinically meaningful survival benefits for patients with EGFR (搜索) wild-type non-squamous non-small cell lung cancer (NSCLC) who have progressed after anti-PD-(L)1 (搜索) immunotherapy. The findings were presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer and the European Society for Medical Oncology Asia Congress 2025.
Addressing Critical Unmet Need in NSCLC
More than 60% of NSCLC patients eventually develop resistance to anti-PD-(L)1 (搜索) therapy, yet no new treatments have been approved in a decade. Nine late-stage trials, including antibody-drug conjugate and anti-PD-(L)1 combination regimens, have failed to show overall survival improvement over docetaxel, the current standard of care for this population.
Post-Hoc Analysis Shows Strong Efficacy Signal
In a mechanism-driven, post-hoc subset analysis of DUBLIN-3, non-squamous EGFR (搜索) wild-type NSCLC patients who progressed after anti-PD-(L)1 (搜索) therapy with at least 3 months of prior clinical benefit showed clinically meaningful improvement with plinabulin plus docetaxel compared to docetaxel alone:
- Median overall survival: 15.8 months versus 11.7 months (HR=0.55)
- Median progression-free survival: 5.6 versus 3.8 months (HR=0.67)
- Objective response rate: 18.2% versus 8.0%
The intent-to-treat EGFR (搜索) wild-type NSCLC population (N=559) demonstrated additional benefits, including improved metastasis-free survival of 15.34 months versus 7.7 months (HR=0.52, p=0.0012) and reduced incidence of new brain metastasis at 4.32% versus 7.83%.
Asian Subset Confirms Global Efficacy
The Asian subset analysis (n=488) showed statistically significant overall survival improvement with plinabulin plus docetaxel achieving 10.8 months versus 8.8 months for docetaxel alone (HR 0.81, p=0.0426). In the mechanism-based non-squamous subgroup, the hazard ratio was 0.69 with a median overall survival benefit of 3 months (p=0.0064). The combination also doubled 2-year and 3-year survival rates, reflecting durable benefit consistent with plinabulin's dendritic-cell maturation mechanism.
Improved Safety Profile
Plinabulin demonstrated marked safety improvements, significantly reducing docetaxel-induced grade 4 neutropenia from 33.58% to 5.13% (p<0.0001) in the global study and from 26.5% to 3.9% (p<0.0001) in the Asian subset. The combination had significantly decreased exposure-adjusted grade 3/4 adverse events versus docetaxel (p=0.0235), supporting prolonged treatment exposure and contributing to improved clinical outcomes.
First-in-Class Mechanism of Action
Plinabulin is a first-in-class, brain-penetrating, dendritic-cell maturation small molecule that has been used in over 700 cancer patients. As a reversible binder at a distinct tubulin (搜索) pocket, plinabulin does not change tubulin dynamics or antagonize tubulin stabilizing agents such as docetaxel, contributing to its differentiated activity and tolerability compared to other tubulin binders.
"These benefits reflect plinabulin's first-in-class dendritic-cell maturation mechanism, which helps to restore antigen presentation and T-cell function after acquired resistance to checkpoint inhibitors," according to the company's analysis.
Path Forward to Registration
BeyondSpring plans to initiate a global Phase 3 DUBLIN-4 trial following its End-of-Phase 2 meeting with the U.S. FDA. DUBLIN-4, together with DUBLIN-3, is expected to support a future NDA submission in non-squamous EGFR (搜索) wild-type NSCLC following progression on anti-PD-(L)1 (搜索) therapy. The DUBLIN-4 study will be a global, double-blind Phase 3 registrational trial evaluating plinabulin plus docetaxel versus docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy.
"Patients who relapse after anti-PD-(L)1 (搜索) therapy represent one of the most significant unmet needs in NSCLC, with docetaxel as the only treatment option while multiple late-stage clinical trials have failed to improve upon it," said Dr. Trevor Feinstein of Piedmont Cancer Center.
Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, stated: "These new analyses suggest plinabulin's unique ability to potentially reinvigorate anti-tumor immune function and improve outcomes in patients who have developed resistance to checkpoint inhibitors. The observed reductions in brain metastasis and the substantial improvement in metastasis-free survival further highlight plinabulin's differentiated clinical profile."